Hikma Pharmaceutical (OP: HKMPF )
31.38 USD -1.22 (-3.75%) Official Closing Price Updated: 3:51 PM EST, Feb 26, 2021 Add to My Watchlist
All news about Hikma Pharmaceutical
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer
February 18, 2021
Partnerships reinforce Hikma's commitment to supporting charitable organisations addressing unmet healthcare needs for underserved patients
Hikma's commitment to environmental performance recognised with "A-" rating in 2020 CDP Global Climate Change Report
January 13, 2021
Hikma launches generic Advair Diskus® following FDA approval
December 17, 2020
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline's Advair Diskus®1...
Markets Up As US Clears Path For Moderna Vaccine Approval
December 16, 2020
European markets have opened positively this morning with Germany’s Dax leading the way up 1.6% as optimism creeps in surrounding vaccination and the prospect of US fiscal stimulus ahead of Central...
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
October 20, 2020
Hikma receives favourable court ruling for its generic Vascepa®
September 03, 2020
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that the US Court of Appeals for the Federal Circuit today upheld a ruling by the US District Court for the...
Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership
August 26, 2020
Hikma Pharmaceuticals PLC (Hikma) announces that its venture capital arm, Hikma Ventures has participated in a CAD4.0 million Series A round of financing for SeamlessMD. The round was led by MEDTEQ,...
Hikma Pharmaceuticals announced overnight that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA has received approval from the Food and Drug Administration for its Icosapent Ethyl Capsules,...
Hikma receives FDA approval for its generic Vascepa®
May 22, 2020
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, today announces that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the...
Is Amarin Stock a Buy?
May 19, 2020
Hikma launches employee matching donation campaign to support local US food banks and pantries
May 11, 2020
Campaign will help address significant increase in demand caused by COVID-19 related job losses and furloughs
Are Amarin's Blockbuster Dreams Over?
April 04, 2020
A ruling that invalidated Amarin’s patents means generic competition for its cardiovascular drug may be right around the corner.
Why Did Amarin's Stock Fall Off a Cliff?
April 02, 2020
1 Cheap Biotech Stock to Buy
March 16, 2020
Could Amarin Be a Millionaire Maker Stock?
January 28, 2020
Vascepa has a good chance of being a blockbuster, but an upcoming patent decision will have the final word.
Ternium SA Is A Strong Buy
January 15, 2018
Tags Stocks / Equities
Hikma Announces Expanded Licensing Agreement with Takeda for New Products in the Middle East and North Africa
August 16, 2017
News Beyond GSK R&D
November 05, 2015
Gold is flat on its back again, with no rise since the start of the year at $1115/oz. Oil meanwhile has gushed in price to $48.18/bbl, up nearly 4.5% just in time for a colder weather.
Tags Stocks / Equities
Step 9 - Financial Review
July 28, 2015
Microsoft is skipping from Windows 8 to Windows 10, and many people wonder what happened to number 9. I think I know; they replaced Windows 9 with Step 9, which requires them to make amends.
UPDATE 1-Hikma profit jumps on strong injectible drugs sales
March 10, 2015
March 11 (Reuters) - Hikma Pharmaceuticals Plc reported a 21 percent rise in full-year pretax profit, helped by a stronger-than-expected performance at its high-margin injectible drugs business.
Hikma profit jumps on strong injectible drug sales
March 10, 2015
March 11 (Reuters) - Hikma Pharmaceuticals Plc reported a 21 percent rise in full-year pretax profit, helped by strong demand for its high-margin injectible drugs, particularly in the United States.
BRIEF-Hikma Pharma says preparing to distribute Colchicine
January 11, 2015
PRESS DIGEST- Financial Times - Dec 22
December 21, 2014
Dec 22 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
UPDATE 1-Hikma raises full-year revenue forecast
November 05, 2014
Nov 6 (Reuters) - Drugmaker Hikma Pharmaceuticals Plc raised its full-year revenue growth target to 7 percent, citing strong demand for its high-margin injectible drugs, particularly in the United...
BRIEF-Hikma says U.S. court grants temporary restraining order on co's Colchicine capsules
October 09, 2014
* Notes that us district court for district of delaware has granted takeda pharmaceuticals u.s. a motion for a temporary restraining order in relation to further distribution of hikma's fda-approved...